926257-13-8

Upstream product

• 118-48-9 isatoic anhydride 
• 89-99-6 2-fluorobenzylamine 

Downstream Products

• 1618654-28-6 2-(tert-butylamino)-3-(2-fluorobenzyl)quinazolin-4(3H)-one 
• 128650-99-7 [3-(2-Fluoro-benzyl)-2,4-dithioxo-3,4-dihydro-2H-quinazolin-1-yl]-acetic acid ethyl ester 
• 128650-97-5 [3-(2-Fluoro-benzyl)-2,4-dioxo-3,4-dihydro-2H-quinazolin-1-yl]-acetic acid ethyl ester 
• 128650-92-0 [3-(2-Fluoro-benzyl)-2-oxo-4-thioxo-3,4-dihydro-2H-quinazolin-1-yl]-acetic acid 
• 128650-91-9 [3-(2-Fluoro-benzyl)-2,4-dioxo-3,4-dihydro-2H-quinazolin-1-yl]-acetic acid 

Relevant academic research and scientific papers

Aldose reductase inhibition by 2,4-oxo and thioxo derivatives of 1,2,3,4-tetrahydroquinazoline

Inhibitors of aldose reductase are believed to be useful for the treatment of diabetic complications.Original acetic acids and their thioxo derivatives have been synthesized and examined for their ability to inhibit aldose reductase in vitro and in vivo.Most were active in vitro on rat lens aldose reductase in the 10-7 molar range.Compound V16, which has a (2'-fluoro-4'-bromo)benzyl substituent on nitrogen N-3 was found in hypergalactosemic rats to be a good inhibitor of galactitol accumulation in sciatic nerves andto prevent cataract formation.

One-pot synthesis of 2-amino-4(3H)-quinazolinones via ring-opening of isatoic anhydride and palladium-catalyzed oxidative isocyanide-insertion

An efficient and practical two-step process has been developed for the synthesis of 2-amino-4(3H)-quinazolinones via ring-opening of isatoic anhydride and palladium-catalyzed oxidative isocyanide-insertion in one pot. This regioselective procedure could construct a wide range of 2-amino-4(3H)- quinazolinones in moderate to excellent yields. Furthermore, the methodology also had distinct advantages of easily accessible starting materials and operational simplicity. the Partner Organisations 2014.

Synthesis and in vitro study of platelet antiaggregant activity of some 4-quinazolinone derivatives

Some new 4-quinazolinones were prepared. Their antiplatelet activity was evaluated in vitro with respect to aggregation induced by ADP, collagen, arachidonic acid and the platelet serotonin release reaction. Most molecules showed an inhibiting power similar to that of acetylsalicylic acid under the same conditions, and even greater when aggregation was induced by ADP. Reduction of the 4-quinazolinone derivatives to their 1,2,3,4-tetrahydroquinazoline homologues produced an increase in platelet inhibitory action except when ADP is the inductor.